Previous Article in Journal
Exploration of the Binding Site of Arachidonic Acid in gp63 of Leishmania mexicana and in Orthologous Proteins in Clinically Important Parasites
Previous Article in Special Issue
Patterns, Outcomes and Economic Burden of Primary vs. Secondary Bloodstream Infections: A Single Center, Cross-Sectional Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 13
Issue 9
10.3390/pathogens13090719
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Genomic Insights into Vietnamese Extended-Spectrum β-Lactamase-9-Producing Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Belonging to High-Risk Clone ST357 Obtained from Bulgarian Intensive Care Unit Patients

by
Tanya Strateva
1,*,
Alexander Stratev
2,3 and
Slavil Peykov
1,4,5
1
Department of Medical Microbiology “Corr. Mem. Prof. Ivan Mitov, MD, DMSc”, Faculty of Medicine, Medical University of Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria
2
Intensive Care Unit, University Multiprofile Hospital for Active Treatment ‘St. Ivan Rilski’, 15 Acad. Ivan Geshov Blvd., 1431 Sofia, Bulgaria
3
Department of Anaesthesiology and Intensive Care, Faculty of Medicine, Medical University of Sofia, 1 St. Georgi Sofiyski Str., 1431 Sofia, Bulgaria
4
Department of Genetics, Faculty of Biology, University of Sofia ‘St. Kliment Ohridski’, 8 Dragan Tzankov Blvd., 1164 Sofia, Bulgaria
5
BioInfoTech Laboratory, Sofia Tech Park, 111 Tsarigradsko Shose Blvd., 1784 Sofia, Bulgaria
*
Author to whom correspondence should be addressed.
Pathogens 2024, 13(9), 719; https://doi.org/10.3390/pathogens13090719 (registering DOI)
Submission received: 27 July 2024 / Revised: 22 August 2024 / Accepted: 23 August 2024 / Published: 25 August 2024
(This article belongs to the Special Issue Hospital-Acquired Infections and Multidrug-Resistant (MDR) Pathogens)
Browse Figures
Versions Notes

Abstract

:
Extensively drug-resistant P. aeruginosa (XDR-PA) has been highlighted as a serious public health threat. The present study aimed to explore the genomic characteristics of two Vietnamese extended-spectrum β-lactamase-9 (VEB-9)-producing XDR-PA isolates from Bulgaria in comparison to all blaVEB-9-positive strains with available genomes. The isolates designated Pae51 and Pae52 were obtained from tracheobronchial aspirates of intensive care unit (ICU) patients. Antimicrobial susceptibility testing, whole-genome sequencing, RT-qPCR, and phylogenomic analysis were performed. Pae51 and Pae52 were resistant to most antipseudomonal β-lactams including carbapenems, aminoglycosides, and fluoroquinolones but remained susceptible to colistin and cefiderocol. Numerous resistance determinants were detected: blaVEB-9, blaPDC-3, blaOXA-10, blaOXA-50, aac(6′)-II, ant(2″)-Ia, ant(3″)-IIa, aph(3′)-IIb, cprP, catB7, dfrB2, sul1, fosA, and tet(A). Both isolates carried complex integrons with blaVEB-9 and tet(A) embedded next to the conservative 3′ end sequences. A variety of virulence factors were also identified, including the type III secretion system exotoxin U. Pae51 and Pae52 differed by only four SNPs and belonged to the high-risk clone ST357. To our knowledge, this is the first report of blaVEB-9-positive XDR-PA isolates in Bulgaria presenting a detailed genomic analysis. The development of novel antimicrobial strategies for such pathogens should be an essential part of infection control stewardship practices in ICU wards.

1. Introduction

Pseudomonas aeruginosa, a ubiquitous Gram-negative bacterium considered one of the paradigms of antimicrobial resistance (AMR), is among the main causes of hospital-acquired and chronic, hard-to-eradicate infections associated with high healthcare costs, as well as significant morbidity and mortality rates [1,2]. It is one of the six leading mortality-causing pathogens, which were collectively accountable for 929,000 deaths attributable to AMR and 3.57 million deaths associated with AMR in 2019 worldwide [3]. Predisposing factors for infections due to P. aeruginosa include mechanical ventilation, catheterization, burn victims, innate or acquired immunodeficiencies, immunosuppressive therapy, cystic fibrosis, and metabolic disorders [4,5,6,7,8,9]. P. aeruginosa is mainly considered an opportunistic, nosocomial pathogen, which is commonly found in intensive care units (ICUs) and surgical settings, where the extensive use of antimicrobials has allowed for the selection of these microorganisms [10]. During the global pandemic, it established itself as one of the most common pathogens causing respiratory co-infections and bacteremia in critically ill COVID-19 patients [11,12].
The treatment of hospital-acquired infections (HAIs) caused by P. aeruginosa is challenging because of the organism’s intrinsic resistance to multiple antibiotics and its remarkable ability to acquire practical resistance to all relevant antipseudomonal antibiotics [13]. Therefore, carbapenem-resistant P. aeruginosa (CRPA) has been highlighted by the World Health Organization (WHO) as a major threat with critical priority for the development of new antibiotics [14]. This growing threat results from its extraordinary capacity to develop AMR via chromosomal mutations and from the increasing prevalence of transferable AMR determinants, particularly those encoding carbapenem-hydrolyzing enzymes and extended-spectrum β-lactamases (ESBLs) [15,16]. Worryingly, these mechanisms are often present simultaneously and confer complex resistant phenotypes. The European Centre for Disease Prevention and Control (ECDC) and U.S. Centers for Disease Control and Prevention classify such therapeutically problematic isolates of P. aeruginosa as multidrug-resistant (MDR-PA), extensively drug-resistant (XDR-PA), and pandrug-resistant (PDR-PA), while the Infectious Diseases Society of America/National Institutes of Health (IDSA/NIH) defines them as isolates with difficult-to-treat resistance (DTR-PA) [17,18].
Several surveys have provided evidence for the existence of ten XDR/DTR international P. aeruginosa high-risk clonal lineages, which have been successfully adapted to hospital settings worldwide [19,20]. Some of these, sequence types ST235, ST357, ST308, and ST298, include strains characterized by both problematic AMR and a highly virulent phenotype associated with a high mortality rate, likely due to the production of the ExoU cytotoxin [21]. In severe P. aeruginosa infections, the phospholipase activity of the type III secretion system (T3SS) ExoU effector protein induces lysis of target host cells and results in the poorest clinical outcomes [22,23].
Beyond molecular epidemiology analysis and a phenotypic assessment of resistance and virulence mechanisms, whole-genome sequencing (WGS) studies are generating relevant information to elucidate the evolving resistome/virulome of P. aeruginosa high-risk clones [24,25,26]. The application of WGS to AMR monitoring provides a deep understanding of the genetic mechanisms involved and easy identification of novel variants of ESBLs and metallo-β-lactamases (MBLs), which are most often the focus of current studies. On the other hand, high-resolution subtyping, comparing the genomes of P. aeruginosa strains of different geographic origins with identical genetic AMR determinants, is a powerful tool for discovering their evolutionary and epidemiological relationships.
Vietnamese extended-spectrum β-lactamase (VEB)-type enzymes of molecular class A and functional group 2be are among the most common β-lactamases identified in clinical P. aeruginosa isolates [20]. Their hydrolytic profile includes carboxypenicillins, ureidopenicillins, third and fourth generation cephalosporins, and aztreonam [27]. The in vitro activity of VEB-type ESBLs is well inhibited by clavulanate, but inhibition by avibactam is variable [28]. The detection of VEB ESBLs in P. aeruginosa strains began in the late 1990s and continues today with the identification of novel variants of the first enzyme in this group, VEB-1.
The present study aimed to explore the genomic characteristics of two VEB-9-producing XDR-PA isolates from ICU patients treated at a Bulgarian university hospital in comparison to all blaVEB-9-positive P. aeruginosa strains with available genomes.

2. Materials and Methods

2.1. Bacterial Strains and Clinical Case Presentation

Two XDR-PA respiratory isolates carrying determinants of a VEB-type ESBL variant previously undescribed in Bulgaria were identified during a WGS project regarding the resistome of nosocomial CRPA isolates. They were obtained from critically ill patients with ventilator-associated pneumonia (VAP) admitted to the University Hospital “St. Ivan Rilski” (405 beds). The hospital is a tertiary care hospital, located in the capital of Bulgaria, Sofia.
The first P. aeruginosa Pae51 isolate (designated Pae51) was obtained at the beginning of February 2020 from a tracheobronchial aspirate of a 26-year-old male with an intramedullary lymphoma tumor of the cervical spine. The patient had been admitted to the Clinic of Neurosurgery, where he underwent surgical decompression (laminectomy at the C4–C6) and tumor removal, several days prior to the isolation of Pae51. After the surgical procedure, he was transferred to the ICU with stable vital signs, spontaneous breathing via an endotracheal tube and persisting pre-operative neurological deficit in the upper and lower extremities. The early postoperative period was complicated by a developing weakness in the respiratory muscles and the onset of hypercapnia and hypoxemia, which required the initiation of controlled mechanical ventilation with positive end-expiratory pressure. During the next two weeks, the patient’s condition did not improve, and he developed pneumonia and septicemia. The blood culture taken was positive for Enterococcus faecalis. It was then decided that the patient should be moved to a specialized hospital in order to treat the respiratory failure.
The second P. aeruginosa Pae52 isolate (designated Pae52) was obtained at the end of April 2020 also from the tracheobronchial aspirate of a 68-year-old male with acute subarachnoid hemorrhage. The patient underwent emergency endovascular embolization of an aneurysm defect to the anterior communicating artery, several weeks prior to the isolation of Pae52. After the procedure, he was admitted to the ICU with signs of a newly developed ischemic lesion in the left hemisphere. He was then placed in a medically induced coma with thiopental and controlled mechanical ventilation was initiated. During the prolonged stay in the ICU, the patient never regained consciousness or spontaneous breathing. His condition deteriorated and became critical, manifesting with signs of pneumonia, septic shock, and worsening multiple organ failure. Despite the treatment, nearly two months after his hospitalization, the patient died from his illness.
P. aeruginosa ATCC 27,853 was used as a control strain for species identification and antimicrobial susceptibility testing.

2.2. Species Identification

Species identification was carried out using the BD Phoenix M50 automated system (BD, Franklin Lakes, NJ, USA). The identification of Pae51 and Pae52 was confirmed by analyzing the assembled draft genome sequence using the Microbial Genomes Atlas (MiGA) Web server [29]. The included workflow for the National Center for Biotechnology Information (NCBI) Genome Database, prokaryotic section, was followed with default settings.

2.3. Antimicrobial Susceptibility Testing

The antimicrobial susceptibility testing (AST) of the VEB-9-producing P. aeruginosa isolates was performed using the minimal inhibitory concentration (MIC) gradient method (MIC Test Strip; Liofilchem, Roseto degli Abruzzi, Italy) or the broth microdilution (BMD) method (ComASP Cefiderocol and ComASP Colistin, Liofilchem), according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) version 14.0, 2024 guidelines, with the following antimicrobial agents: piperacillin-tazobactam (TZP), ceftazidime (CAZ), cefepime (FEP), cefiderocol (CFDC), imipenem (IMP), meropenem (MEM), aztreonam (ATM), amikacin (AMK), tobramycin (TOB), ciprofloxacin (CIP), levofloxacin (LVX), and colistin (COL) [30]. MICs of several additional antibiotics, such as ceftazidime-avibactam (CZA), ceftolozane-tazobactam (CTT), imipenem-relebactam (IMR), and meropenem-vaborbactam (MEV), were determined using the Sensititre Gram Negative MDRGNXXF AST Plates (Thermo Fisher Scientific Inc., Waltham, MA, USA) following the manufacturer’s protocol.

2.4. Definitions of MDR-PA, XDR-PA, PDR-PA, and DTR-PA Isolates

According to the international expert proposal [17], MDR-PA isolates are non-susceptible to at least one agent in three or more categories, whereas XDR-PA isolates are non-susceptible to at least one agent in all but two or fewer categories, including aminoglycosides (AMK, TOB), antipseudomonal carbapenems (IMP, MEM), antipseudomonal cephalosporins (CAZ, FEP), antipseudomonal fluoroquinolones (CIP, LVX), antipseudomonal penicillins + β-lactamase inhibitors (TZP, ticarcillin-clavulanic acid), monobactams (ATM), and polymyxins (COL, polymyxin B). PDR-PA isolates are non-susceptible to all antimicrobial agents listed.
DTP-PA is defined by non-susceptibility to all of the following antimicrobials: CAZ, FEP, TZP, IMP, MEM, CIP, LVX, and ATM [18].

2.5. DNA Isolation

Total DNA from the investigated strains was isolated using the DNeasy Blood and Tissue Kit (QIAGEN, Hilden, Germany), according to the manufacturer’s instructions, from 3 mL of overnight cultures inoculated with a single colony.

2.6. Whole-Genome Sequencing (WGS)

The two blaVEB-9-positive P. aeruginosa isolates underwent WGS to facilitate comprehensive analyses of their resistomes and virulomes. The extracted genomic DNA was randomly fragmented, size-selected, ligated to adapters, and then PCR-amplified. Following these steps, the generated libraries were sequenced on an Illumina NovaSeq 6000 platform (Novogene, Cambridge, UK), producing 2 × 150 bp paired-end reads.

2.7. Draft Genome Assembly

The entire procedure encompassed several steps: quality control (FastQC v0.11.9, https://www.bioinformatics.babraham.ac.uk/projects/fastqc/, accessed on 15 July 2024), raw read preprocessing (Trimmomatic v0.38) [31], genome assembly (SPAdes v3.12.0) [32], and draft genome metrics evaluation (Quast v5.2.0) [33]. All software tools applied were part of the Galaxy online platform [34] and were operated with default parameters unless otherwise specified.

2.8. Resistome Analysis

Both assembled draft genome sequences were screened for AMR genes using ABRicate (v1.0.1) with the following settings: the Comprehensive Antibiotic Resistance Database (CARD) [35], minimum DNA identity (70%), and minimum DNA coverage (60%).
Additionally, the gyrA and parC coding sequences were manually analyzed for mutations in their quinolone resistance-determining regions (QRDRs). Finally, the full lengths of oprD and mexT were screened for carbapenem resistance-related missense, frameshift, and indel variants. Both analyses were performed using blastn comparisons with the corresponding sequences in the P. aeruginosa PAO1 strain (Gene IDs: 881970, 880417).

2.9. Reverse Transcription Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR)

The mRNA levels of the oprD gene, encoding the outer membrane porin OprD, were measured by two-step RT-qPCR as previously described [36]. The imipenem-susceptible P. aeruginosa PAO1 strain was used as a calibrator for the evaluation step. In brief, DNase-treated RNA isolated from cultures in the log phase was subjected to reverse transcription using the SuperScript™ III First-Strand Synthesis System (Thermo Fisher Scientific, Carlsbad, CA, USA) with random hexamers. Concurrently, a control reverse transcription reaction without the enzyme was performed to exclude the possibility of genomic DNA contamination. The resulting cDNAs were appropriately diluted, and 2 μL of each dilution was combined with 8 μL of primer mix [36] and 10 μL of iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA) to prepare the qPCR reactions. They were conducted using a Rotor-Gene Q real-time PCR System (QIAGEN). The oprD mRNA expression was calculated using the 2−ΔΔCt method [37] with an expression rate of ≤30% compared to the P. aeruginosa PAO1 strain considered indicative of diminished gene expression.

2.10. Virulome Analysis

The assembled genomes of both isolates were screened for virulence determinants using the VFanalyzer tool available at the Virulence Factor Database (VFDB) [38] with default settings.

2.11. Multilocus Sequence Typing (MLST) and O-Antigen Serotyping Analyses

The MLST analysis was conducted on the assembled contigs using the MLST tool (Galaxy Version 2.19.0, https://usegalaxy.eu/). The utilized P. aeruginosa MLST scheme incorporates internal fragments of the following seven housekeeping genes: acsA (acetyl coenzyme A synthetase), aroE (shikimate dehydrogenase), guaA (GMP synthase), mutL (DNA mismatch repair protein), nuoD (NADH dehydrogenase I chain C, D), ppsA (phosphoenolpyruvate synthase), and trpE (anthralite synthetase component I) [39].
The Pae51 and Pae52 isolates were assigned O-serotypes in silico using the Pseudomonas aeruginosa serotyper (PAst) tool v1.0 [40].

2.12. Phylogenomic Analysis

The phylogenomic analysis included our VEB-9-producing XDR-PA isolates (n = 2) and all blaVEB-9-positive P. aeruginosa strains with genomes deposited in the NCBI Nucleotide database (n = 20) and The Pseudomonas Genome Database [41] (n = 116) as of 1 July 2024 (search keywords: Pseudomonas aeruginosa, VEB-9). All sequences from both sources underwent quality evaluation (Quast v5.2.0) [33], and draft genomes with a total number of contigs (>1000 bp) greater than 200 and/or an L50 value greater than 25 were excluded from the subsequent analysis. The remaining nonduplicate genomes (n = 76) were subjected to MLST analysis via the above-mentioned MLST tool and screening for AMR genes (ABRicate v1.0.1). After confirming their VEB-9 positivity, all sequences were annotated using Prokka v1.14.6 [42]. Subsequently, the pangenome pipeline Roary v3.13.0 [43] was employed to generate a core gene alignment with a minimum blastp identity of 95% and a core definition threshold of 99%. A phylogenetic tree was then constructed using the RAxML program v8.2.12, employing the neighbor-joining clustering method with 1000 bootstraps [44]. The Interactive Tree Of Life portal was utilized to create a graphical representation of the phylogenetic tree [45].

3. Results

3.1. Antimicrobial Susceptibility

The AST profiles of the two P. aeruginosa isolates studied are presented in Table 1. As shown, Pae51 and Pae52 were resistant to most antipseudomonal β-lactams including carbapenems (MIC values of IMP and MEM > 32 mg/L), aminoglycosides, and fluoroquinolones, but remained susceptible to colistin (1 mg/L) and cefiderocol (0.5–1 mg/L). Both isolates were classified as XDR-PA, as well as DTR-PA.

3.2. Draft Genome Assemblies: Evaluation and Comparison

The two assembled draft genomes showed an identical size of 6.72 Mb, and their GC% content was approximately 66% (Table 2). These values are comparable with the accessible data from sequenced P. aeruginosa genomes. Also, Pae51 and Pae52 belonged to the epidemic high-risk ST357, which is the founder of the CC357 clonal complex, and the P. aeruginosa O11 serotype.

3.3. WGS-Based Resistome Analysis

Resistome analysis revealed the existence of blaVEB-9, encoding the VEB-9 ESBL, in both isolates studied. In addition, Pae51 and Pae52 possessed genes for the class C AmpC β-lactamase known as Pseudomonas-Derived Cephalosporinase (blaPDC-3), two genes for class D β-lactamases (blaOXA-10 and blaOXA-50), several determinants encoding aminoglycoside-modifying enzymes, crpP (a CrpP enzyme able to phosphorylate ciprofloxacin), catB7 (chloramphenicol acetyltransferase B7), dfrB2 (dihydrofolate reductase B2), sul1 (dihydropteroate synthase type-1), fosA (Mn2+- and K+-dependent glutathione S-transferase associated with fosfomycin resistance), and tet(A) (Tet(A) efflux pump). All identified AMR genes in the two sequenced genomes are illustrated in Figure 1. A comparison of the QRDRs of Pae51 and Pae52 with the corresponding region of P. aeruginosa PAO1 revealed that the investigated isolates possessed two amino acid substitutions (p.T83I in gyrA and p.S87L in parC) with a role in fluoroquinolone resistance.
Our manual analysis of the genetic environment of the blaVEB-9 gene in the assembled genomes of Pae51 and Pae52 revealed characteristic features indicative of a class 1 integron with a complex structure (Figure 2). The blaVEB-9 and tet(A) genes were located near its 3′ end, which is indicated by the presence of sul1. Various genes related to mobile genetic elements are present upstream and downstream (Figure 2, marked in black). A comparative BLASTn analysis of the entire sequence in the TnCentral database [46] revealed various hits, with Tn5086-CP054343 and Tn1412-L36547 showing the highest max and total scores, respectively.
The size and sequencing coverage of the corresponding contigs suggest that the blaVEB-9 genes, carried by the P. aeruginosa Pae51 and Pae52 isolates, are located on their chromosomes.
The coding sequence of the oprD gene was screened for mutations, revealing that both Pae51 and Pae52 harbor identical sequence variants. All identified missense and indel variants, compared to the corresponding region in P. aeruginosa PAO1, are shown in Figure 3. Additionally, the OprD porin produced by Pae51 and Pae52 was compared to the Non-redundant Protein Sequence (nr) database via BLASTP, resulting in a single hit with 100% identity and coverage (AWF58599.1). This sequence belonged to the clinical P. aeruginosa strain AR_0443 (CP029147.1), which is reported to be resistant to imipenem (32 mg/L), meropenem (>8 mg/L), and doripenem (>8 mg/L). A resistome analysis of its complete genome found no genes encoding known carbapenemases.
The mexT gene, encoding for a regulator of the MexE-MexF-OprN multidrug efflux system of P. aeruginosa, was found to possess an 8-bp (GGCCAGCC) deletion (Figure 3), which leads to a frameshift in the coding sequence.

3.4. Expression Analysis of oprD Gene

The performed RT-qPCR analysis showed that the expression levels of the oprD genes in Pae51 and Pae52 were diminished compared to the carbapenem-susceptible P. aeruginosa PAO1 strain used as a calibrator (relative expression: 0.21 and 0.28, respectively).

3.5. WGS-Based Virulome Analysis

Both isolates harbored a wide array of virulence-related genes encoding proteins involved in adherence, antimicrobial activity, antiphagocytosis, quorum sensing, iron uptake, secretion, the production of biosurfactant, and extracellular enzymes. Their complete list is given in Figure 4. All identified virulence-related genes are presented and grouped according to the classes defined in the Virulence Factor Database (VFDB) [38]. Also, the operon structures given are according to the Pseudomonas Genome DB [41].
Several virulence factors associated with type IV pili (fimT, fimU, pilA, pilC, pilV, pilW, and pilY2) and the biosynthesis of phenazines (phzA2, phzB2, phzC2, phzD2, phzE1, phzE2, phzF1, phzF2, and phzG1) were absent in Pae51 and Pae52 compared to the reference strain P. aeruginosa PAO1. The only difference between Pae51 and Pae52 was the presence of pilE in the genome of the former isolate, as illustrated in Figure 4.
The genomes of Pae51 and Pae52 contained genes encoding the type III secretion system effector proteins ExoT and ExoY. Additionally, they also harbored exoU, unlike the P. aeruginosa PAO1 strain, which possesses an exoS+/exoU– genotype. Many T3SS genes (listed in Figure 4) were also detected, indicating a functional T3SS machinery.

3.6. Phylogenomic Analysis of blaVEB-9-positive P. aeruginosa Strains

To examine the epidemiology of the investigated isolates, a set of 78 nonduplicate blaVEB-9-Positive P. aeruginosa genomes were collected as previously described. The geographic origins of these strains are given in Figure 5a. Next, a phylogenetic tree was constructed based on sequence variants in the core gene alignment, as depicted above. The result is shown in Figure 5b.
Our isolates, designated Pae51 and Pae52, were notably similar, differing by only four SNPs in their core genome regions. The genome most closely related to them was GCF_032231105.1, which belonged to a clinical P. aeruginosa Pae3125 strain from Varna (Bulgaria). This strain has been subjected to WGS, but our careful search found no published results on its genome in the literature.
As illustrated in the figure, 74.4% (58/78) of the blaVEB-9-containing isolates subjected to phylogenomic analysis belonged to the high-risk ST357 and were ubiquitously distributed across Africa, Asia, and Europe. The remaining isolates with a determined MLST profile were assigned to ST111 (2/78), ST235 (6/78), ST664 (1/78), ST2592 (6/78), and ST3904 (2/78).
All β-lactamase-encoding genes identified in the blaVEB-9-positive genomes included in the phylogenomic analysis are also listed in Figure 5b. The genetic determinants encoding OXA-10, OXA-50, and PDC-3 exhibit the highest levels of co-occurrence with blaVEB-9, at 91%, 91%, and 87.2% of the isolates, respectively. It is also noteworthy that 24 of the 78 isolates analyzed (30.8%) were found to be blaNDM-1-positive.

4. Discussion

P. aeruginosa is a common cause of HAIs, particularly in ICUs and surgical wards, which manifest as pneumonia, surgical site infections, urinary tract infections, and bacteremia [1]. According to the ECDC Annual Epidemiological Report 2020, 11,124 (12.7%) of patients staying in an ICU for more than two days developed at least one ICU-acquired HAI, and P. aeruginosa was the most frequently identified pathogen in ICU-acquired pneumonia (21.1%) and third, after Escherichia coli and Enterococcus spp., in urinary tract infections (14.3%). Furthermore, the incidence of CRPA isolates in these hospital wards in the European Union/European Economic Area (EU/EEA) countries was estimated at 26% [47].
Recent data on AMR show drastic differences in the prevalence of both nosocomial CRPA and MDR-PA isolates within the WHO EU/EEA Region. These problematic isolates tend to increase following the axes “west–east” and “north–south”, highlighting the Balkans, of which Bulgaria is a part, as a high-priority area [48]. In 2021, among the reported invasive P. aeruginosa isolates in Bulgaria, of which 54.2% were obtained from ICU patients, 32.5% and 31.3% were CRPA and MDR-PA, respectively [49].
The clinical P. aeruginosa isolates described in our investigation were problematic ICU pathogens. Antimicrobial susceptibility testing revealed retained activity of only two of the antibiotics studied: COL and CFDC. The clinical use of COL, an old polymyxin antibiotic available since the 1950s, has recently resurfaced as salvage therapy for severe Gram-negative infections, due to superbugs, including XDR-PA, which are resistant to all other antimicrobial agents. However, its therapeutic application should be limited both due to toxicity and low serum and tissue concentrations [50,51]. Despite recent approvals of novel antibiotics, there remain relatively few active treatment options for CRPA infections. Choices focus on the β-lactam–β-lactamase inhibitor (BL–BLI) combinations, such as CTT, CZA, and IMR, as well as the siderophore cephalosporin, CFDC [52]. Several studies have shown that MEV has activity against some clinical CRPA and MDR-PA strains [53,54]. Nevertheless, MEV, unlike the other new approved antibiotics, is not included as an option for DTR-PA infections in guidelines from the IDSA [55]. All the aforementioned BL–BLI combinations did not demonstrate in vitro activity against the two XDR-PA isolates subjected to the present study. Recently, Sid Ahmed et al. found that blaVEB-9 carriage in MDR-PA isolates from Qatar correlates with resistance to CZA and/or CTT. The authors reported that co-resistance to these antimicrobials is associated with the presence of blaVEB-9, blaPDC-35, blaVIM-2, blaOXA-10, and blaOXA-488, whilst CTT resistance alone is correlated with blaVEB-9, blaPDC-35, and blaOXA-488 [56]. AMR determinants encoding class A (blaVEB-9), class C (blaPDC-3), and class D (blaOXA-10 and blaOXA-50) β-lactamases were also identified in the P. aeruginosa Pae51 and Pae52 isolates. It is also worth mentioning the emergence of non-MBL-producing Enterobacterales demonstrating resistance to the new BL-BLI drugs. Recently Muresu et al. reported a Klebsiella pneumoniae isolate obtained from an Italian critically ill patient with COVID-19-related pneumonia demonstrating a remarkable resistance profile to several antimicrobial drugs, including CZA, MEV, and IMR. The authors found that the coexistence of both class A (KPC-31) and class D (OXA-181) carbapenemases, coupled with porin mutations, may be associated with the observed XDR profile [57].
Of the newly approved antibiotics, only CFDC demonstrated high in vitro activity (MIC = 0.5–1 mg/L) against the tested carbapenem-resistant and extensively drug-resistant P. aeruginosa isolates. It is a first-in-class catechol-substituted siderophore cephalosporin that has potent activity against a broad spectrum of aerobic Gram-negative pathogens, including carbapenem-resistant Enterobacterales and non-fermenting bacteria such as P. aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia [58,59]. CFDC was approved by the U.S. Food and Drug Administration in late 2019 for the treatment of complicated urinary tract infections in adult patients, including pyelonephritis, and nosocomial pneumonia, including VAP, caused by susceptible aerobic Gram-negative bacteria [60]. Later, in 2020, CFDC was approved by the European Medicines Agency for complicated Gram-negative infections in adults with limited treatment options [61]. The efficacy and safety of CFDC have been shown in phase 2 and phase 3 clinical trials in patients with serious Gram-negative infections [62,63,64], but patients in these studies typically had other potential treatment options that allowed for randomization and trial enrollment. Thus, these trials provide limited information on the clinical effectiveness of the antibiotic for patients suffering from P. aeruginosa infections for whom no alternative treatment options exist. It is worth mentioning that, currently, CFDC has not yet been implemented in clinical practice in Bulgaria.
CFDC possesses the ability to overcome carbapenemases of different molecular classes and exhibit high stability against AmpC cephalosporinases, porin mutations, and efflux pumps complexly implicated in the carbapenem resistance of clinical P. aeruginosa strains [52,65]. Recent results from the SENTRY Antimicrobial Surveillance Program are very encouraging. These showed that 99.6% of the P. aeruginosa isolates tested and obtained in 2020 from the USA and Europe were susceptible to CFDC when interpreted according to the Clinical and Laboratory Standards Institute criteria. The antibiotic activity was also excellent against XDR-PA (97.3%), which showed lower susceptibility to the new BL–BLI combinations (IMR, 73%, CZA, 73.4%, and CTT, 72.3%). CFDC retained complete susceptibility in IMR-resistant isolates and remarkable susceptibility in CZA- and CTT-resistant isolates (91.6% and 88.3%, respectively), as well as with combined resistance to the three new antimicrobials (100%) [66]. A systematic review and meta-analysis performed by Karakonstantis et al., based on 78 studies, 87% of which were published between 2020 and 2023, showed excellent in vitro activity of CFDC against clinical isolates of P. aeruginosa. According to the presented results, the overall prevalence of CFDC-non-susceptible P. aeruginosa isolates was 1.4% [95% CI 0.5–4.0%], and among CRPAs, it was 3.5% [95% CI 1.6–7.8%] [67]. Data on the in vitro CFDC susceptibility of clinical CRPAs in Bulgaria are scarce and concern only single-MBL-producing isolates. A recent study found 100% susceptibility to CFDC in the testing of eight New Delhi metallo-β-lactamase-1 (NDM-1)-producing P. aeruginosa isolates from a tertiary hospital in Sofia [68]. In contrast, Stoykov et al. reported three P. aeruginosa isolates also from Sofia producing IMP-type MBLs, two of which showed resistance to CFDC (MIC values of 4–8 mg/L) [69].
The widespread use of β-lactams and the adaptive capacity of the P. aeruginosa genome have led to a significant increase in the antimicrobial resistance of the pathogen over the past decade. Acquired resistance to these antibiotics is associated with both enzymatic and non-enzymatic mechanisms. Enzymatic mechanisms include the production of various types of ESBLs, carbapenem-hydrolyzing enzymes, mainly of class B (MBLs) and less frequently of class A, and the hyperproduction of the chromosomal AmpC β-lactamase of class C [70,71]. Despite the phenotypically manifested carbapenem resistance of the Pae51 and Pae52 isolates detailed in this study, WGS-based resistome analysis did not identify any AMR determinants for either class B- or class A-acquired carbapenemases. The only identified genes associated with β-bactam resistance were blaVEB-9, which encodes the VEB-9 ESBL of class A, blaPDC-3 (class C intrinsic Pseudomonas-Derived Cephalosporinase-1), blaOXA-10, and blaOXA-50 (both class D β-lactamases).
The subject of this study, VEB-9 (formerly known as VEB-1a) ESBL, was initially detected in two clinical P. aeruginosa isolates from ICU patients in Kuwait that demonstrated resistance to CAZ and cefotaxime, as well as a synergistic effect between CAZ and clavulanic acid [72]. As a representative of molecular subclass A2 and functional group 2be, VEB-9 is responsible for the resistance of the studied Pae51 and Pae52 isolates to ureidopenicillins, extended-spectrum cephalosporins, including CAZ and FEP, and aztreonam [27,73]. The only reported variant of VEB-type ESBLs among MDR-PA in Bulgaria is VEB-1, and previously identified nosocomial blaVEB-1-positive P. aeruginosa isolates have been shown to belong to two international high-risk clones, ST111 and ST244 [74,75,76]. Over the last decade, VEB-9-producing P. aeruginosa isolates have been found in Thailand, Poland, and Qatar [56,77,78,79]. For the first time in Europe, Laudy et al. detected blaVEB-9-positive P. aeruginosa (7.7%) among CAZ-resistant and/or FEP-resistant clinical isolates from four hospitals in Warsaw, Poland, between 2000 and 2014. The authors established the clonal relatedness of the isolates using PFGE typing. All VEB-9 producers were assigned to one pulsotype and two subtypes, PT M and PT Ma/Mb, respectively [78]. Later, Sid Ahmed et al. conducted the WGS of 75 selected MDR-PA clinical isolates collected from several hospitals in Qatar in 2014–2015 to analyze the dominant STs and AMR determinants of β-lactam resistance. VEB-9 was reported to be the most prevalent ESBL (25.3%), and 18 of the 19 blaVEB-9-containing P. aeruginosa isolates were part of the high-risk clones ST235 (n = 8), ST357 (n = 7), and ST308 (n = 3) [79]. As presented above, our VEB-9 producers were also classified as ST357.
The phylogenomic analysis revealed that ¾ of all blaVEB-9-positive P. aeruginosa genomes worldwide also belong to ST357. Alarmingly, 41.3% of these, sourced from India, Kenya, and Tanzania, also carry the blaNDM-1 gene encoding the NDM-1 MBL. The combination of VEB-9 and NDM-1 confers resistance to all β-lactams, including those combined with β-lactamase inhibitors, significantly restricting the available treatment options [80].
The other sequence types were represented by single blaVEB-9-positive strains involved in the phylogenomic analysis. However, ST2592 (n = 6) warrants attention due to its presence across a broad geographic region, including Russia, Ukraine, Germany, and Kazakhstan. The ongoing military conflict in that area could potentially facilitate the rapid spread of VEB-9-producing ST2592 P. aeruginosa isolates. Therefore, increased stewardship practices in the surrounding countries may be necessary to manage this risk.
The blaVEB-9 gene in Pae51 and Pae52 was found to be part of a complex, class 1-like integron located on the chromosome. Despite its location, the presence of numerous genes encoding proteins necessary for the transfer of mobile genetic elements, situated nearby, underscores the potential for horizontal gene transfer to other isolates. Extensive comparison with annotated prokaryotic transposons showed components of Tn3-family transposons Tn5086-CP054343 (found in E. coli SCU-164) and Tn1412-L36547 (described in P. aeruginosa 2293E), suggesting complex genetic transpositions and rearrangements in the VEB-9 region. A BLASTN search using the blaVEB-9 gene and its surrounding regions from our isolates against the Nucleotide collection (nr/nt) database revealed 14 hits in complete P. aeruginosa genomes, each with query coverage of 98% or higher. This suggests that the organization of the blaVEB-9 context in the Pae51 and Pae52 isolates is common for the species.
In Gram-negative pathogens, carbapenem hydrolysis seems not to be restricted to the main carbapenem-hydrolyzing class D β-lactamase (CHDL) groups, including OXA-23, OXA-24/40, OXA-48, and OXA-51 found in Acinetobacter species. The OXA-10 β-lactamase of class D identified in Pae51 and Pae52 may also possess weak carbapenemase activity at a level that is the same as or higher than that of, e.g., OXA-58 [81]. There are opposing claims in the literature about the nature of the other class D β-lactamase detected, OXA-50, and its derivatives. Some authors present them as naturally occurring in all P. aeruginosa strains [82,83], while others refer them to acquired oxacillinases with carbapenemase activity [84]. A few years ago, Petrova et al. reported three OXA-50-producing CRPA isolates from a university hospital in Plovdiv, Bulgaria, which lacked AMR determinants for class B and A carbapenemases but demonstrated weak carbapenemase activity when performing the modified Hodge test [85,86]. The authors recognized a secondary role for OXA-50 in carbapenem resistance, and overexpression of the MexXY-OprM efflux pump combined with OprD deficiency and/or overexpression of the MexAB-OprM pump were identified as the primary mechanisms [84].
Our analysis of the oprD coding sequence revealed numerous missense mutations and a frameshift mutation, the majority of which impact the loop regions of the encoded porin. Similar observations have been previously reported in CRPA isolates, indicating that alterations in OprD reduce its ability to bind imipenem, thereby conferring resistance to this antibiotic [87]. Additionally, the subsequent expression analysis established reduced oprD expression, which also contributes to the observed imipenem resistance in the Pae51 and Pae52 isolates. It was accompanied by an 8-bp deletion in the mexT gene, which resulted in a frameshift. This variant was present in all 29 MDR P. aeruginosa clinical isolates collected from various laboratories in Kerala, India, between 2012 and 2016 in an earlier study [87], and oprD was downregulated in 89.7% (n = 26) of these isolates. It is worth noting that, unlike most Resistance Nodulation Division-type efflux systems in P. aeruginosa, MexT serves as a positive regulator of MexEF-OprN expression. This observation supports a previous hypothesis that in strains with wild-type and/or inactivated mexT, mutations in other, yet unidentified genes may be crucial for the hyperexpression of mexEF-oprN and the reduced production of OprD [88].
Consistent with previous studies showing an association of ST357 with the exoU+/exoS− T3SS genotype [20,21], our virolome analysis revealed that Pae51 and Pae52 (ST357) possess this specific genotype. ExoS and ExoU T3SS effector proteins play an essential role in infectious pathogenesis. ExoS leads to delayed apoptotic cell death, whereas ExoU is associated with a highly cytotoxic phenotype of P. aeruginosa and induces rapid host–cell lysis [22]. ExoU is considered the major T3SS cytotoxin because it has the greatest impact on disease severity, being associated with severe acute lung injury, sepsis, and mortality [89,90,91]. It is recognized as an independent risk factor for early mortality related to P. aeruginosa bloodstream infections [91]. Furthermore, the secretion of the ExoU cytotoxin is considered a marker for highly virulent P. aeruginosa strains obtained from patients with hospital-acquired pneumonia (HAP) [92], such as the Pae51 and Pae52 isolates we studied. Different investigations have shown that exoS and exoU are almost always mutually exclusive in the genome of P. aeruginosa [21,89,93,94,95], which was also found in the present study. This finding may be related to the possibility that the expression of each of these genes provides increased fitness in different ecological niches [96]. In contrast to these results, there are reports of the simultaneous existence of exoS and exoU in a significant number of clinical P. aeruginosa isolates [97,98,99,100,101,102].
As mentioned, the O-specific antigen in P. aeruginosa lipopolysaccharide was determined via in silico serotyping. The analysis showed that both isolates studied belong to the O11 serotype. Regarding serotype, our finding is consistent with the existing literature, which demonstrates a strong association between O11 and the MDR phenotype [103]. The O11 serotype is usually linked to the exoU-positive genotype as well as to the high-risk clone ST357 [21], as was also found in our study. Interestingly, the O11 serotype is associated with a worse prognosis in HAP/VAP and bloodstream infections among critically ill patients [103,104].

5. Conclusions

To the best of our knowledge, this is the first report of blaVEB-9-positive XDR-PA isolates in Bulgaria presenting detailed genomic and phylogenomic analyses. Pae51 and Pae52 belonged to high-risk clone ST357, as well as to the O11 serotype and exoU-positive genotype, both associated with a worse prognosis for HAI outcomes in critically ill patients. Moreover, this study provides extensive information on the worldwide distribution of VEB-9-producing P. aeruginosa isolates combined with their MLST and β-lactamase-encoding gene profiles. Genetic determinants encoding OXA-10, OXA-50, and PDC-3 β-lactamases showed the highest levels of co-occurrence with blaVEB-9, and most isolates (74.4%) were assigned to high-risk clone ST357.
HAIs caused by therapeutically problematic and highly virulent P. aeruginosa pose a growing threat to public health. Therefore, the development of novel antimicrobial strategies for such pathogens should be an essential part of infection control stewardship practices in hospitals, especially in ICU wards.

6. Limitations of the Study

The number of the included blaVEB-9 P. aeruginosa isolates obtained from the aforementioned university hospital was low. The main purpose of the present study was to explore the genomic characteristics (resistance and virulence determinants) of two VEB-9-producing XDR-PA isolates in comparison to all blaVEB-9-positive P. aeruginosa strains with available genomes originating from all over the world. This study does not provide information regarding the prevalence and antimicrobial resistance of VEB-9-producing P. aeruginosa isolates in either a specific hospital or the country. The expression of mexEF-oprN was not measured.

Author Contributions

Conceptualization, T.S., A.S. and S.P.; methodology T.S., A.S. and S.P.; software, S.P. and A.S.; validation, T.S. and S.P.; formal analysis, T.S. and S.P.; investigation, T.S., A.S. and S.P.; resources, T.S. and S.P.; data curation, T.S. and S.P.; writing—original draft preparation, T.S.; writing—review and editing, T.S. and S.P.; visualization, T.S. and S.P.; supervision, T.S.; project administration, T.S. and S.P.; funding acquisition, S.P. All authors have read and agreed to the published version of the manuscript.

Funding

The whole-genome sequencing was supported by a grant from the Council of Medical Science of the Medical University of Sofia (Sofia, Bulgaria), project no. 8201/24.11.2023, contract no. D-100/29.05.2024 (S.P.).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

All patients signed the usual informed consent statement after admission to the intensive care unit. In the present study, we worked only with bacterial isolates. A brief description of the clinical cases and relevant hospital-acquired infections preceding the isolation of Pae51/Pae52 is presented, but none of the patients’ personal data were used.

Data Availability Statement

The whole-genome shotgun sequencing projects of the P. aeruginosa Pae51 and Pae52 isolates were deposited in GenBank under BioProject accession number PRJNA1138419 (assemblies JBFQFS000000000 and JBFQFR000000000, respectively).

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Reynolds, D.; Kollef, M. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs 2021, 81, 2117–2131. [Google Scholar] [CrossRef] [PubMed]
  2. Horcajada, J.P.; Montero, M.; Oliver, A.; Sorlí, L.; Luque, S.; Gómez-Zorrilla, S.; Benito, N.; Grau, S. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin. Microbiol. Rev. 2019, 32, e00031-19. [Google Scholar] [CrossRef] [PubMed]
  3. Murray, C.J.L.; Ikuta, K.S.; Sharara, F.; Swetschinski, L.; Robles Aguilar, G.; Gray, A.; Han, C.; Bisignano, C.; Rao, P.; Wool, E.; et al. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. Lancet 2022, 399, 629–655. [Google Scholar] [CrossRef] [PubMed]
  4. Migiyama, Y.; Sakata, S.; Iyama, S.; Tokunaga, K.; Saruwatari, K.; Tomita, Y.; Saeki, S.; Okamoto, S.; Ichiyasu, H.; Sakagami, T. Airway Pseudomonas aeruginosa Density in Mechanically Ventilated Patients: Clinical Impact and Relation to Therapeutic Efficacy of Antibiotics. Crit. Care 2021, 25, 59. [Google Scholar] [CrossRef] [PubMed]
  5. Gomersall, J.; Mortimer, K.; Hassan, D.; Whitehead, K.A.; Slate, A.J.; Ryder, S.F.; Chambers, L.E.; El Mohtadi, M.; Shokrollahi, K. Ten-Year Analysis of Bacterial Colonisation and Outcomes of Major Burn Patients with a Focus on Pseudomonas aeruginosa. Microorganisms 2023, 12, 42. [Google Scholar] [CrossRef]
  6. Rossi, E.; La Rosa, R.; Bartell, J.A.; Marvig, R.L.; Haagensen, J.A.J.; Sommer, L.M.; Molin, S.; Johansen, H.K. Pseudomonas aeruginosa Adaptation and Evolution in Patients with Cystic Fibrosis. Nat. Rev. Microbiol. 2021, 19, 331–342. [Google Scholar] [CrossRef]
  7. Paprocka, P.; Durnaś, B.; Mańkowska, A.; Król, G.; Wollny, T.; Bucki, R. Pseudomonas aeruginosa Infections in Cancer Patients. Pathogens 2022, 11, 679. [Google Scholar] [CrossRef]
  8. Jarzynka, S.; Makarewicz, O.; Weiss, D.; Minkiewicz-Zochniak, A.; Iwańska, A.; Skorupa, W.; Padzik, M.; Augustynowicz-Kopeć, E.; Olędzka, G. The Impact of Pseudomonas aeruginosa Infection in Adult Cystic Fibrosis Patients—A Single Polish Centre Study. Pathogens 2023, 12, 1440. [Google Scholar] [CrossRef]
  9. Yakout, M.A.; Abdelwahab, I.A. Diabetic Foot Ulcer Infections and Pseudomonas aeruginosa Biofilm Production During the COVID-19 Pandemic. J. Pure Appl. Microbiol. 2022, 16, 138–146. [Google Scholar] [CrossRef]
  10. Behzadi, P.; Baráth, Z.; Gajdács, M. It’s Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa. Antibiotics 2021, 10, 42. [Google Scholar] [CrossRef]
  11. Yang, S.; Hua, M.; Liu, X.; Du, C.; Pu, L.; Xiang, P.; Wang, L.; Liu, J. Bacterial and Fungal Co-Infections among COVID-19 Patients in Intensive Care Unit. Microbes Infect. 2021, 23, 104806. [Google Scholar] [CrossRef] [PubMed]
  12. Bongiovanni, M.; Barda, B. Pseudomonas aeruginosa Bloodstream Infections in SARS-CoV-2 Infected Patients: A Systematic Review. J. Clin. Med. 2023, 12, 2252. [Google Scholar] [CrossRef] [PubMed]
  13. Jangra, V.; Sharma, N.; Chhillar, A.K. Therapeutic Approaches for Combating Pseudomonas aeruginosa Infections. Microbes Infect. 2022, 24, 104950. [Google Scholar] [CrossRef]
  14. Tacconelli, E.; Carrara, E.; Savoldi, A.; Harbarth, S.; Mendelson, M.; Monnet, D.L.; Pulcini, C.; Kahlmeter, G.; Kluytmans, J.; Carmeli, Y.; et al. Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis. Lancet Infect. Dis. 2018, 18, 318–327. [Google Scholar] [CrossRef]
  15. López-Causapé, C.; Cabot, G.; Del Barrio-Tofiño, E.; Oliver, A. The Versatile Mutational Resistome of Pseudomonas aeruginosa. Front. Microbiol. 2018, 9, 685. [Google Scholar] [CrossRef]
  16. Jean, S.-S.; Harnod, D.; Hsueh, P.-R. Global Threat of Carbapenem-Resistant Gram-Negative Bacteria. Front. Cell. Infect. Microbiol. 2022, 12, 823684. [Google Scholar] [CrossRef] [PubMed]
  17. Magiorakos, A.-P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [Google Scholar] [CrossRef]
  18. Kadri, S.S.; Adjemian, J.; Lai, Y.L.; Spaulding, A.B.; Ricotta, E.; Prevots, D.R.; Palmore, T.N.; Rhee, C.; Klompas, M.; Dekker, J.P.; et al. Difficult-to-Treat Resistance in Gram-Negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-Line Agents. Clin. Infect. Dis. 2018, 67, 1803–1814. [Google Scholar] [CrossRef]
  19. Oliver, A.; Mulet, X.; López-Causapé, C.; Juan, C. The Increasing Threat of Pseudomonas aeruginosa High-Risk Clones. Drug Resist. Updates 2015, 21–22, 41–59. [Google Scholar] [CrossRef]
  20. Del Barrio-Tofiño, E.; López-Causapé, C.; Oliver, A. Pseudomonas aeruginosa Epidemic High-Risk Clones and Their Association with Horizontally-Acquired β-Lactamases: 2020 Update. Int. J. Antimicrob. Agents 2020, 56, 106196. [Google Scholar] [CrossRef]
  21. Oliver, A.; Rojo-Molinero, E.; Arca-Suarez, J.; Beşli, Y.; Bogaerts, P.; Cantón, R.; Cimen, C.; Croughs, P.D.; Denis, O.; Giske, C.G.; et al. Pseudomonas aeruginosa Antimicrobial Susceptibility Profiles, Resistance Mechanisms and International Clonal Lineages: Update from ESGARS-ESCMID/ISARPAE Group. Clin. Microbiol. Infect. 2024, 30, 469–480. [Google Scholar] [CrossRef]
  22. Jurado-Martín, I.; Sainz-Mejías, M.; McClean, S. Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. IJMS 2021, 22, 3128. [Google Scholar] [CrossRef] [PubMed]
  23. Foulkes, D.M.; McLean, K.; Zheng, Y.; Sarsby, J.; Haneef, A.S.; Fernig, D.G.; Winstanley, C.; Berry, N.; Kaye, S.B. A Pipeline to Evaluate Inhibitors of the Pseudomonas aeruginosa Exotoxin U. Biochem. J. 2021, 478, 647–668. [Google Scholar] [CrossRef]
  24. Jaillard, M.; Van Belkum, A.; Cady, K.C.; Creely, D.; Shortridge, D.; Blanc, B.; Barbu, E.M.; Dunne, W.M.; Zambardi, G.; Enright, M.; et al. Correlation between Phenotypic Antibiotic Susceptibility and the Resistome in Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 2017, 50, 210–218. [Google Scholar] [CrossRef]
  25. Del Barrio-Tofiño, E.; Zamorano, L.; Cortes-Lara, S.; López-Causapé, C.; Sánchez-Diener, I.; Cabot, G.; Bou, G.; Martínez-Martínez, L.; Oliver, A.; GEMARA-SEIMC/REIPI Pseudomonas study Group; et al. Spanish Nationwide Survey on Pseudomonas aeruginosa Antimicrobial Resistance Mechanisms and Epidemiology. J. Antimicrob. Chemother. 2019, 74, 1825–1835. [Google Scholar] [CrossRef]
  26. Kabic, J.; Fortunato, G.; Vaz-Moreira, I.; Kekic, D.; Jovicevic, M.; Pesovic, J.; Ranin, L.; Opavski, N.; Manaia, C.M.; Gajic, I. Dissemination of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa in Serbian Hospital Settings: Expansion of ST235 and ST654 Clones. IJMS 2023, 24, 1519. [Google Scholar] [CrossRef] [PubMed]
  27. Strateva, T.; Yordanov, D. Pseudomonas aeruginosa—A Phenomenon of Bacterial Resistance. J. Med. Microbiol. 2009, 58, 1133–1148. [Google Scholar] [CrossRef]
  28. Castanheira, M.; Simner, P.J.; Bradford, P.A. Extended-Spectrum β -Lactamases: An Update on Their Characteristics, Epidemiology and Detection. JAC-Antimicrob. Resist. 2021, 3, dlab092. [Google Scholar] [CrossRef] [PubMed]
  29. Rodriguez-R, L.M.; Gunturu, S.; Harvey, W.T.; Rosselló-Mora, R.; Tiedje, J.M.; Cole, J.R.; Konstantinidis, K.T. The Microbial Genomes Atlas (MiGA) Webserver: Taxonomic and Gene Diversity Analysis of Archaea and Bacteria at the Whole Genome Level. Nucleic Acids Res. 2018, 46, W282–W288. [Google Scholar] [CrossRef]
  30. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 14.0. 2024. Available online: https://eucast.org (accessed on 5 July 2024).
  31. Bolger, A.M.; Lohse, M.; Usadel, B. Trimmomatic: A Flexible Trimmer for Illumina Sequence Data. Bioinformatics 2014, 30, 2114–2120. [Google Scholar] [CrossRef]
  32. Bankevich, A.; Nurk, S.; Antipov, D.; Gurevich, A.A.; Dvorkin, M.; Kulikov, A.S.; Lesin, V.M.; Nikolenko, S.I.; Pham, S.; Prjibelski, A.D.; et al. SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing. J. Comput. Biol. 2012, 19, 455–477. [Google Scholar] [CrossRef]
  33. Gurevich, A.; Saveliev, V.; Vyahhi, N.; Tesler, G. QUAST: Quality Assessment Tool for Genome Assemblies. Bioinformatics 2013, 29, 1072–1075. [Google Scholar] [CrossRef] [PubMed]
  34. The Galaxy Community; Afgan, E.; Nekrutenko, A.; Grüning, B.A.; Blankenberg, D.; Goecks, J.; Schatz, M.C.; Ostrovsky, A.E.; Mahmoud, A.; Lonie, A.J.; et al. The Galaxy Platform for Accessible, Reproducible and Collaborative Biomedical Analyses: 2022 Update. Nucleic Acids Res. 2022, 50, W345–W351. [Google Scholar] [CrossRef]
  35. Alcock, B.P.; Huynh, W.; Chalil, R.; Smith, K.W.; Raphenya, A.R.; Wlodarski, M.A.; Edalatmand, A.; Petkau, A.; Syed, S.A.; Tsang, K.K.; et al. CARD 2023: Expanded Curation, Support for Machine Learning, and Resistome Prediction at the Comprehensive Antibiotic Resistance Database. Nucleic Acids Res. 2023, 51, D690–D699. [Google Scholar] [CrossRef]
  36. Nazari, M.; Ahmadi, H.; Hosseinzadeh, S.; Sahebkar, A.; Khademi, F. Imipenem Resistance Associated with Amino Acid Alterations of the OprD Porin in Pseudomonas aeruginosa Clinical Isolates. Acta Microbiol. Immunol. Hung. 2023, 70, 206–212. [Google Scholar] [CrossRef] [PubMed]
  37. Livak, K.J.; Schmittgen, T.D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef]
  38. Liu, B.; Zheng, D.; Zhou, S.; Chen, L.; Yang, J. VFDB 2022: A General Classification Scheme for Bacterial Virulence Factors. Nucleic Acids Res. 2022, 50, D912–D917. [Google Scholar] [CrossRef] [PubMed]
  39. Curran, B.; Jonas, D.; Grundmann, H.; Pitt, T.; Dowson, C.G. Development of a Multilocus Sequence Typing Scheme for the Opportunistic Pathogen Pseudomonas aeruginosa. J. Clin. Microbiol. 2004, 42, 5644–5649. [Google Scholar] [CrossRef]
  40. Thrane, S.W.; Taylor, V.L.; Lund, O.; Lam, J.S.; Jelsbak, L. Application of Whole-Genome Sequencing Data for O-Specific Antigen Analysis and In Silico Serotyping of Pseudomonas aeruginosa Isolates. J. Clin. Microbiol. 2016, 54, 1782–1788. [Google Scholar] [CrossRef] [PubMed]
  41. Winsor, G.L.; Griffiths, E.J.; Lo, R.; Dhillon, B.K.; Shay, J.A.; Brinkman, F.S.L. Enhanced Annotations and Features for Comparing Thousands of Pseudomonas Genomes in the Pseudomonas Genome Database. Nucleic Acids Res. 2016, 44, D646–D653. [Google Scholar] [CrossRef]
  42. Seemann, T. Prokka: Rapid Prokaryotic Genome Annotation. Bioinformatics 2014, 30, 2068–2069. [Google Scholar] [CrossRef] [PubMed]
  43. Page, A.J.; Cummins, C.A.; Hunt, M.; Wong, V.K.; Reuter, S.; Holden, M.T.G.; Fookes, M.; Falush, D.; Keane, J.A.; Parkhill, J. Roary: Rapid Large-Scale Prokaryote Pan Genome Analysis. Bioinformatics 2015, 31, 3691–3693. [Google Scholar] [CrossRef] [PubMed]
  44. Stamatakis, A. RAxML Version 8: A Tool for Phylogenetic Analysis and Post-Analysis of Large Phylogenies. Bioinformatics 2014, 30, 1312–1313. [Google Scholar] [CrossRef]
  45. Letunic, I.; Bork, P. Interactive Tree Of Life (iTOL) v5: An Online Tool for Phylogenetic Tree Display and Annotation. Nucleic Acids Res. 2021, 49, W293–W296. [Google Scholar] [CrossRef] [PubMed]
  46. Ross, K.; Varani, A.M.; Snesrud, E.; Huang, H.; Alvarenga, D.O.; Zhang, J.; Wu, C.; McGann, P.; Chandler, M. TnCentral: A Prokaryotic Transposable Element Database and Web Portal for Transposon Analysis. mBio 2021, 12, e02060-21. [Google Scholar] [CrossRef] [PubMed]
  47. European Centre for Disease Prevention and Control. Healthcare-associated infections acquired in intensive care units. In ECDC. Annual Epidemiological Report for 2020; ECDC: Stockholm, Sweden, 2024; Available online: https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-acquired-intensive-care-units-annual (accessed on 19 July 2024).
  48. Peykov, S.; Strateva, T. Whole-Genome Sequencing-Based Resistome Analysis of Nosocomial Multidrug-Resistant Non-Fermenting Gram-Negative Pathogens from the Balkans. Microorganisms 2023, 11, 651. [Google Scholar] [CrossRef]
  49. Antimicrobial Resistance Surveillance in Europe 2023–2021 Data. European Centre for Disease Prevention and Control and World Health Organization: Stockholm, Sweden, 2023. Available online: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2023-2021-data (accessed on 19 July 2024).
  50. El-Sayed Ahmed, M.A.E.-G.; Zhong, L.-L.; Shen, C.; Yang, Y.; Doi, Y.; Tian, G.-B. Colistin and Its Role in the Era of Antibiotic Resistance: An Extended Review (2000–2019). Emerg. Microbes Infect. 2020, 9, 868–885. [Google Scholar] [CrossRef] [PubMed]
  51. Coppola, N.; Maraolo, A.E.; Onorato, L.; Scotto, R.; Calò, F.; Atripaldi, L.; Borrelli, A.; Corcione, A.; De Cristofaro, M.G.; Durante-Mangoni, E.; et al. Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion. Antibiotics 2022, 11, 1263. [Google Scholar] [CrossRef]
  52. Canton, R.; Doi, Y.; Simner, P.J. Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infections: A Case for Cefiderocol. Expert Rev. Anti-Infect. Ther. 2022, 20, 1077–1094. [Google Scholar] [CrossRef]
  53. Patel, T.S.; Kaye, K.S.; Krishnan, J.; Marshall, V.; Mills, J.; Albin, O.; Young, C.; Smith, A.; Lephart, P.; Pogue, J.M. Comparative In Vitro Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of Pseudomonas aeruginosa. Open Forum Infect. Dis. 2019, 6, S251. [Google Scholar] [CrossRef]
  54. Shortridge, D.; Carvalhaes, C.; Deshpande, L.; Castanheira, M. Activity of Meropenem/Vaborbactam and Comparators against Gram-Negative Isolates from Eastern and Western European Patients Hospitalized with Pneumonia Including Ventilator-Associated Pneumonia (2014–19). J. Antimicrob. Chemother. 2021, 76, 2600–2605. [Google Scholar] [CrossRef] [PubMed]
  55. Tamma, P.D.; Aitken, S.L.; Bonomo, R.A.; Mathers, A.J.; Van Duin, D.; Clancy, C.J. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-Lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin. Infect. Dis. 2022, 75, 187–212. [Google Scholar] [CrossRef] [PubMed]
  56. Sid Ahmed, M.A.; Khan, F.A.; Hadi, H.A.; Skariah, S.; Sultan, A.A.; Salam, A.; Al Khal, A.L.; Söderquist, B.; Ibrahim, E.B.; Omrani, A.S.; et al. Association of blaVIM-2, blaPDC-35, blaOXA-10, blaOXA-488 and blaVEB-9 β-Lactamase Genes with Resistance to Ceftazidime–Avibactam and Ceftolozane–Tazobactam in Multidrug-Resistant Pseudomonas aeruginosa. Antibiotics 2022, 11, 130. [Google Scholar] [CrossRef]
  57. Muresu, N.; Del Rio, A.; Fox, V.; Scutari, R.; Alteri, C.; Are, B.M.; Terragni, P.; Sechi, I.; Sotgiu, G.; Piana, A. Genomic Characterization of KPC-31 and OXA-181 Klebsiella pneumoniae Resistant to New Generation of β-Lactam/β-Lactamase Inhibitor Combinations. Antibiotics 2022, 12, 10. [Google Scholar] [CrossRef]
  58. Choi, J.J.; McCarthy, M.W. Cefiderocol: A Novel Siderophore Cephalosporin. Expert Opin. Investig. Drugs 2018, 27, 193–197. [Google Scholar] [CrossRef] [PubMed]
  59. Satlin, M.J.; Simner, P.J.; Slover, C.M.; Yamano, Y.; Nagata, T.D.; Portsmouth, S. Cefiderocol Treatment for Patients with Multidrug—And Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program. Antimicrob. Agents Chemother. 2023, 67, e00194-23. [Google Scholar] [CrossRef] [PubMed]
  60. Shionogi Inc. Fetcroja (cefiderocol). In Prescribing Information; Shionogi Inc.: Florham Park, NJ, USA, 2021; Available online: https://www.shionogi.com/content/dam/shionogi/si/products/pdf/fetroja.pdf (accessed on 20 July 2024).
  61. European Medicines Agency. Fetcroja (cefiderocol). An overview of Fetcroja and Why It Is Authorised in the EU. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/fetcroja (accessed on 20 July 2024).
  62. Portsmouth, S.; Van Veenhuyzen, D.; Echols, R.; Machida, M.; Ferreira, J.C.A.; Ariyasu, M.; Tenke, P.; Nagata, T.D. Cefiderocol versus Imipenem-Cilastatin for the Treatment of Complicated Urinary Tract Infections Caused by Gram-Negative Uropathogens: A Phase 2, Randomised, Double-Blind, Non-Inferiority Trial. Lancet Infect. Dis. 2018, 18, 1319–1328. [Google Scholar] [CrossRef]
  63. Wunderink, R.G.; Matsunaga, Y.; Ariyasu, M.; Clevenbergh, P.; Echols, R.; Kaye, K.S.; Kollef, M.; Menon, A.; Pogue, J.M.; Shorr, A.F.; et al. Cefiderocol versus High-Dose, Extended-Infusion Meropenem for the Treatment of Gram-Negative Nosocomial Pneumonia (APEKS-NP): A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial. Lancet Infect. Dis. 2021, 21, 213–225. [Google Scholar] [CrossRef]
  64. Bassetti, M.; Echols, R.; Matsunaga, Y.; Ariyasu, M.; Doi, Y.; Ferrer, R.; Lodise, T.P.; Naas, T.; Niki, Y.; Paterson, D.L.; et al. Efficacy and Safety of Cefiderocol or Best Available Therapy for the Treatment of Serious Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria (CREDIBLE-CR): A Randomised, Open-Label, Multicentre, Pathogen-Focused, Descriptive, Phase 3 Trial. Lancet Infect. Dis. 2021, 21, 226–240. [Google Scholar] [CrossRef]
  65. Losito, A.R.; Raffaelli, F.; Del Giacomo, P.; Tumbarello, M. New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. Antibiotics 2022, 11, 579. [Google Scholar] [CrossRef]
  66. Shortridge, D.; Streit, J.M.; Mendes, R.; Castanheira, M. In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. Microbiol. Spectr. 2022, 10, e02712-21. [Google Scholar] [CrossRef]
  67. Karakonstantis, S.; Rousaki, M.; Vassilopoulou, L.; Kritsotakis, E.I. Global Prevalence of Cefiderocol Non-Susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: A Systematic Review and Meta-Analysis. Clin. Microbiol. Infect. 2024, 30, 178–188. [Google Scholar] [CrossRef] [PubMed]
  68. Strateva, T.; Keuleyan, E.; Peykov, S. Genomic Insights into NDM-1-Producing Pseudomonas aeruginosa: Current Status in a Bulgarian Tertiary Hospital and on the Balkans. Acta Microbiol. Immunol. Hung. 2024, 71, 99–109. [Google Scholar] [CrossRef] [PubMed]
  69. Stoikov, I.; Ivanov, I.N.; Donchev, D.; Teneva, D.; Dobreva, E.; Hristova, R.; Sabtcheva, S. Genomic Characterization of IMP-Producing Pseudomonas aeruginosa in Bulgaria Reveals the Emergence of IMP-100, a Novel Plasmid-Mediated Variant Coexisting with a Chromosomal VIM-4. Microorganisms 2023, 11, 2270. [Google Scholar] [CrossRef] [PubMed]
  70. Glen, K.A.; Lamont, I.L. β-Lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects. Pathogens 2021, 10, 1638. [Google Scholar] [CrossRef]
  71. Torrens, G.; Hernández, S.B.; Ayala, J.A.; Moya, B.; Juan, C.; Cava, F.; Oliver, A. Regulation of AmpC-Driven β-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling. mSystems 2019, 4, e00524-19. [Google Scholar] [CrossRef]
  72. Poirel, L.; Rotimi, V.O.; Mokaddas, E.M.; Karim, A.; Nordmann, P. VEB-1-like Extended-Spectrum ß-Lactamases in Pseudomonas aeruginosa, Kuwait. Emerg. Infect. Dis. 2001, 7, 468–470. [Google Scholar] [CrossRef]
  73. Philippon, A.; Slama, P.; Dény, P.; Labia, R. A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes. Clin. Microbiol. Rev. 2016, 29, 29–57. [Google Scholar] [CrossRef]
  74. Strateva, T.; Ouzounova-Raykova, V.; Markova, B.; Todorova, A.; Marteva-Proevska, Y.; Mitov, I. Widespread Detection of VEB-1-Type Extended-Spectrum Beta-Lactamases Among Nosocomial Ceftazidime-Resistant Pseudomonas aeruginosa Isolates in Sofia, Bulgaria. J. Chemother. 2007, 19, 140–145. [Google Scholar] [CrossRef]
  75. Strateva, T.; Ouzounova-Raykova, V.; Markova, B.; Todorova, A.; Marteva-Proevska, Y.; Mitov, I. Problematic Clinical Isolates of Pseudomonas aeruginosa from the University Hospitals in Sofia, Bulgaria: Current Status of Antimicrobial Resistance and Prevailing Resistance Mechanisms. J. Med. Microbiol. 2007, 56, 956–963. [Google Scholar] [CrossRef]
  76. Vatcheva-Dobrevska, R.; Mulet, X.; Ivanov, I.; Zamorano, L.; Dobreva, E.; Velinov, T.; Kantardjiev, T.; Oliver, A. Molecular Epidemiology and Multidrug Resistance Mechanisms of Pseudomonas aeruginosa Isolates from Bulgarian Hospitals. Microb. Drug Resist. 2013, 19, 355–361. [Google Scholar] [CrossRef] [PubMed]
  77. Lahiri, S.D.; Alm, R.A. Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition. Antimicrob. Agents Chemother. 2016, 60, 3183–3186. [Google Scholar] [CrossRef]
  78. Laudy, A.E.; Róg, P.; Smolińska-Król, K.; Ćmiel, M.; Słoczyńska, A.; Patzer, J.; Dzierżanowska, D.; Wolinowska, R.; Starościak, B.; Tyski, S. Prevalence of ESBL-Producing Pseudomonas aeruginosa Isolates in Warsaw, Poland, Detected by Various Phenotypic and Genotypic Methods. PLoS ONE 2017, 12, e0180121. [Google Scholar] [CrossRef] [PubMed]
  79. Sid Ahmed, M.A.; Khan, F.A.; Sultan, A.A.; Söderquist, B.; Ibrahim, E.B.; Jass, J.; Omrani, A.S. β-Lactamase-Mediated Resistance in MDR-Pseudomonas aeruginosa from Qatar. Antimicrob. Resist. Infect. Control 2020, 9, 170. [Google Scholar] [CrossRef]
  80. Ferous, S.; Anastassopoulou, C.; Pitiriga, V.; Vrioni, G.; Tsakris, A. Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa. Antibiotics 2024, 13, 285. [Google Scholar] [CrossRef] [PubMed]
  81. Antunes, N.T.; Lamoureaux, T.L.; Toth, M.; Stewart, N.K.; Frase, H.; Vakulenko, S.B. Class D β-Lactamases: Are They All Carbapenemases? Antimicrob. Agents Chemother. 2014, 58, 2119–2125. [Google Scholar] [CrossRef] [PubMed]
  82. Girlich, D.; Naas, T.; Nordmann, P. Biochemical Characterization of the Naturally Occurring Oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2004, 48, 2043–2048. [Google Scholar] [CrossRef] [PubMed]
  83. Naas, T.; Oueslati, S.; Bonnin, R.A.; Dabos, M.L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B.I. Beta-Lactamase Database (BLDB)—Structure and Function. J. Enzym. Inhib. Med. Chem. 2017, 32, 917–919. [Google Scholar] [CrossRef] [PubMed]
  84. Petrova, A.; Feodorova, Y.; Miteva-Katrandzhieva, T.; Petrov, M.; Murdjeva, M. First Detected OXA-50 Carbapenem-Resistant Clinical Isolates Pseudomonas aeruginosa from Bulgaria and Interplay between the Expression of Main Efflux Pumps, OprD and Intrinsic AmpC. J. Med. Microbiol. 2019, 68, 1723–1731. [Google Scholar] [CrossRef]
  85. Lee, K.; Chong, Y.; Shin, H.B.; Kim, Y.A.; Yong, D.; Yum, J.H. Modified Hodge and EDTA-Disk Synergy Tests to Screen Metallo-β-Lactamase-Producing Strains of Pseudomonas and Acinetobacter Species. Clin. Microbiol. Infect. 2001, 7, 88–91. [Google Scholar] [CrossRef]
  86. Pasteran, F.; Veliz, O.; Rapoport, M.; Guerriero, L.; Corso, A. Sensitive and Specific Modified Hodge Test for KPC and Metallo-Beta- Lactamase Detection in Pseudomonas aeruginosa by Use of a Novel Indicator Strain, Klebsiella pneumoniae ATCC 700603. J. Clin. Microbiol. 2011, 49, 4301–4303. [Google Scholar] [CrossRef] [PubMed]
  87. Suresh, M.; Skariyachan, S.; Narayanan, N.; Pullampara Rajamma, J.; Panickassery Ramakrishnan, M.K. Mutational Variation Analysis of oprD Porin Gene in Multidrug-Resistant Clinical Isolates of Pseudomonas aeruginosa. Microb. Drug Resist. 2020, 26, 869–879. [Google Scholar] [CrossRef] [PubMed]
  88. Sobel, M.L.; Neshat, S.; Poole, K. Mutations in PA2491 (mexS) Promote MexT-Dependent mexEF-oprN Expression and Multidrug Resistance in a Clinical Strain of Pseudomonas aeruginosa. J. Bacteriol. 2005, 187, 1246–1253. [Google Scholar] [CrossRef] [PubMed]
  89. Juan, C.; Peña, C.; Oliver, A. Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections. J. Infect. Dis. 2017, 215, S44–S51. [Google Scholar] [CrossRef]
  90. Howell, H.A.; Logan, L.K.; Hauser, A.R. Type III Secretion of ExoU Is Critical during Early Pseudomonas aeruginosa Pneumonia. mBio 2013, 4, e00032-13. [Google Scholar] [CrossRef]
  91. Pena, C.; Cabot, G.; Gomez-Zorrilla, S.; Zamorano, L.; Ocampo-Sosa, A.; Murillas, J.; Almirante, B.; Pomar, V.; Aguilar, M.; Granados, A.; et al. Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections. Clin. Infect. Dis. 2015, 60, 539–548. [Google Scholar] [CrossRef]
  92. Schulert, G.S.; Feltman, H.; Rabin, S.D.P.; Martin, C.G.; Battle, S.E.; Rello, J.; Hauser, A.R. Secretion of the Toxin ExoU Is a Marker for Highly Virulent Pseudomonas aeruginosa Isolates Obtained from Patients with Hospital-Acquired Pneumonia. J. Infect. Dis. 2003, 188, 1695–1706. [Google Scholar] [CrossRef]
  93. Feltman, H.; Schulert, G.; Khan, S.; Jain, M.; Peterson, L.; Hauser, A.R. Prevalence of Type III Secretion Genes in Clinical and Environmental Isolates of Pseudomonas aeruginosa. Microbiology 2001, 147, 2659–2669. [Google Scholar] [CrossRef]
  94. Hauser, A.R. The Type III Secretion System of Pseudomonas aeruginosa: Infection by Injection. Nat. Rev. Microbiol. 2009, 7, 654–665. [Google Scholar] [CrossRef]
  95. Bradbury, R.S.; Roddam, L.F.; Merritt, A.; Reid, D.W.; Champion, A.C. Virulence Gene Distribution in Clinical, Nosocomial and Environmental Isolates of Pseudomonas aeruginosa. J. Med. Microbiol. 2010, 59, 881–890. [Google Scholar] [CrossRef]
  96. Rutherford, V.; Yom, K.; Ozer, E.A.; Pura, O.; Hughes, A.; Murphy, K.R.; Cudzilo, L.; Mitchell, D.; Hauser, A.R. Environmental Reservoirs for exoS+ and exoU+ Strains of Pseudomonas aeruginosa. Env. Microbiol. Rep. 2018, 10, 485–492. [Google Scholar] [CrossRef] [PubMed]
  97. Finnan, S.; Morrissey, J.P.; O’Gara, F.; Boyd, E.F. Genome Diversity of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients and the Hospital Environment. J. Clin. Microbiol. 2004, 42, 5783–5792. [Google Scholar] [CrossRef] [PubMed]
  98. Morales-Espinosa, R.; Delgado, G.; Espinosa, L.F.; Isselo, D.; Méndez, J.L.; Rodriguez, C.; Miranda, G.; Cravioto, A. Fingerprint Analysis and Identification of Strains ST309 as a Potential High Risk Clone in a Pseudomonas aeruginosa Population Isolated from Children with Bacteremia in Mexico City. Front. Microbiol. 2017, 8, 313. [Google Scholar] [CrossRef] [PubMed]
  99. Malek Mohamad, S.; Rostami, S.; Zamanzad, B.; Gholipour, A.; Drees, F. Detection of Exotoxins and Antimicrobial Susceptibility Pattern in Clinical Pseudomonas aeruginosa Isolates. Avicenna J. Clin. Microbiol. Infect. 2017, 5, 36–40. [Google Scholar] [CrossRef]
  100. Horna, G.; Amaro, C.; Palacios, A.; Guerra, H.; Ruiz, J. High Frequency of the exoU+/exoS+ Genotype Associated with Multidrug-Resistant “High-Risk Clones” of Pseudomonas aeruginosa Clinical Isolates from Peruvian Hospitals. Sci. Rep. 2019, 9, 10874. [Google Scholar] [CrossRef]
  101. Song, Y.; Mu, Y.; Wong, N.-K.; Yue, Z.; Li, J.; Yuan, M.; Zhu, X.; Hu, J.; Zhang, G.; Wei, D.; et al. Emergence of Hypervirulent Pseudomonas aeruginosa Pathotypically Armed with Co-Expressed T3SS Effectors ExoS and ExoU. hLife 2023, 1, 44–56. [Google Scholar] [CrossRef]
  102. Akrami, S.; Ekrami, A.; Jahangirimehr, F.; Yousefi Avarvand, A. High Prevalence of Multidrug-resistant Pseudomonas aeruginosa Carrying Integron and exoA, exoS, and exoU Genes Isolated from Burn Patients in Ahvaz, Southwest Iran: A Retrospective Study. Health Sci. Rep. 2024, 7, e2164. [Google Scholar] [CrossRef]
  103. Recio, R.; Mancheño, M.; Viedma, E.; Villa, J.; Orellana, M.Á.; Lora-Tamayo, J.; Chaves, F. Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence. Antimicrob. Agents Chemother. 2020, 64, e01759-19. [Google Scholar] [CrossRef]
  104. Lu, Q.; Eggimann, P.; Luyt, C.-E.; Wolff, M.; Tamm, M.; François, B.; Mercier, E.; Garbino, J.; Laterre, P.-F.; Koch, H.; et al. Pseudomonas aeruginosa Serotypes in Nosocomial Pneumonia: Prevalence and Clinical Outcomes. Crit. Care 2014, 18, R17. [Google Scholar] [CrossRef]
Pathogens 13 00719 g001
Figure 1. Resistome analysis of two blaVEB-9-positive P. aeruginosa isolates obtained from critically ill patients admitted to the University Hospital “St. Ivan Rilski”, Bulgaria.
Figure 1. Resistome analysis of two blaVEB-9-positive P. aeruginosa isolates obtained from critically ill patients admitted to the University Hospital “St. Ivan Rilski”, Bulgaria.
Pathogens 13 00719 g001
Pathogens 13 00719 g002
Figure 2. Schematic representation of the blaVEB-9 environment in the P. aeruginosa Pae51 and Pae52 isolates (ST357) from Bulgaria. The figure also shows the presence of genes associated with mobile genetic elements and the best matches for the VEB-9 region in the TnCentral database.
Figure 2. Schematic representation of the blaVEB-9 environment in the P. aeruginosa Pae51 and Pae52 isolates (ST357) from Bulgaria. The figure also shows the presence of genes associated with mobile genetic elements and the best matches for the VEB-9 region in the TnCentral database.
Pathogens 13 00719 g002
Pathogens 13 00719 g003
Figure 3. Amino acid sequences of the Pae51/Pae52 OprD sequence aligned with that of the P. aeruginosa PAO1 strain. Color coding in the Pae51/52 line represents similar (conservative—given in blue) and dissimilar (non-conservative—given in red) substitutions, determined by the BLASTP alignment/BLOSUM62 matrix. The loop regions, as determined by the crystal structure of the porin protein, are demarcated with a thick green line over the alignment. Mutations inside loops are marked in green (PAO1 line).
Figure 3. Amino acid sequences of the Pae51/Pae52 OprD sequence aligned with that of the P. aeruginosa PAO1 strain. Color coding in the Pae51/52 line represents similar (conservative—given in blue) and dissimilar (non-conservative—given in red) substitutions, determined by the BLASTP alignment/BLOSUM62 matrix. The loop regions, as determined by the crystal structure of the porin protein, are demarcated with a thick green line over the alignment. Mutations inside loops are marked in green (PAO1 line).
Pathogens 13 00719 g003
Pathogens 13 00719 g004
Figure 4. Virulome analysis of two blaVEB-9-positive P. aeruginosa isolates obtained from critically ill patients admitted to the University Hospital “St. Ivan Rilski”, Bulgaria.
Figure 4. Virulome analysis of two blaVEB-9-positive P. aeruginosa isolates obtained from critically ill patients admitted to the University Hospital “St. Ivan Rilski”, Bulgaria.
Pathogens 13 00719 g004
Pathogens 13 00719 g005aPathogens 13 00719 g005b
Figure 5. Phylogenomic analysis of blaVEB-9-positive P. aeruginosa strains with available genomes in the NCBI Nucleotide and The Pseudomonas Genome Database. (a) geographical origins of the isolates included. Countries displayed in the diagram are labeled with their respective three−letter ISO codes, as specified by the ISO 3166 international standard; (b) phylogenomic tree constructed by calling SNPs from core gene alignment of 78 blaVEB-9-positive isolates from Africa, Asia, Europe, and North America. A presence/absence matrix of β-lactamase-encoding genes is also given.
Figure 5. Phylogenomic analysis of blaVEB-9-positive P. aeruginosa strains with available genomes in the NCBI Nucleotide and The Pseudomonas Genome Database. (a) geographical origins of the isolates included. Countries displayed in the diagram are labeled with their respective three−letter ISO codes, as specified by the ISO 3166 international standard; (b) phylogenomic tree constructed by calling SNPs from core gene alignment of 78 blaVEB-9-positive isolates from Africa, Asia, Europe, and North America. A presence/absence matrix of β-lactamase-encoding genes is also given.
Pathogens 13 00719 g005aPathogens 13 00719 g005b
Table 1. Antimicrobial susceptibility testing of studied VEB-9-producing P. aeruginosa isolates.
Table 1. Antimicrobial susceptibility testing of studied VEB-9-producing P. aeruginosa isolates.
Antimicrobial AgentsMIC [mg/L] and Interpretation
Pae51Pae52
Piperacillin>256 R>256 R
Piperacillin-tazobactam a>256 R>256 R
Ceftazidime>256 R>256 R
Ceftazidime-Avibactam a>32 R>32 R
Cefepime>256 R>256 R
Ceftolozane-Tazobactam a>8 R>8 R
Cefiderocol1 S0.5 S
Imipenem>32 R>32 R
Imipenem-Relebactam a>16 R>16 R
Meropenem>32 R>32 R
Meropenem-Vaborbactam b>16 R>16 R
Aztreonam64 R64 R
Amikacin32 R48 R
Tobramycin16 R16 R
Ciprofloxacin>32 R>32 R
Levofloxacin>32 R>32 R
Colistin1 S1 S
MIC, minimum inhibitory concentration; R, resistant; S, susceptible. a The concentration of tazobactam/avibactam/relebactam was fixed at 4 mg/L. b The concentration of vaborbactam was fixed at 8 mg/L.
Table 2. Whole genome-based characterization of studied VEB-9-producing P. aeruginosa isolates.
Table 2. Whole genome-based characterization of studied VEB-9-producing P. aeruginosa isolates.
IsolateGenome Size (Mb)GC%N50 (bp)Number of ContigsSerotypeSTAlleles
acsAaroEguaAmutLnuoDppsAtrpE
Pae516.7266.04425,53841O1135724531611
Pae526.7266.03395,42947O1135724531611
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Strateva, T.; Stratev, A.; Peykov, S. Genomic Insights into Vietnamese Extended-Spectrum β-Lactamase-9-Producing Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Belonging to High-Risk Clone ST357 Obtained from Bulgarian Intensive Care Unit Patients. Pathogens 2024, 13, 719. https://doi.org/10.3390/pathogens13090719

AMA Style

Strateva T, Stratev A, Peykov S. Genomic Insights into Vietnamese Extended-Spectrum β-Lactamase-9-Producing Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Belonging to High-Risk Clone ST357 Obtained from Bulgarian Intensive Care Unit Patients. Pathogens. 2024; 13(9):719. https://doi.org/10.3390/pathogens13090719

Chicago/Turabian Style

Strateva, Tanya, Alexander Stratev, and Slavil Peykov. 2024. "Genomic Insights into Vietnamese Extended-Spectrum β-Lactamase-9-Producing Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Belonging to High-Risk Clone ST357 Obtained from Bulgarian Intensive Care Unit Patients" Pathogens 13, no. 9: 719. https://doi.org/10.3390/pathogens13090719

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop